Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

NCT05677490 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05677490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
January 31, 2023
Completion date
November 8, 2028
Enrollment
382 (estimated)
Sites
798

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal adenocarcinoma, advanced gastric adenocarcinoma, advanced gastroesophageal junction adenocarcinoma, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, metastatic esophageal adenocarcinoma, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, unresectable esophageal adenocarcinoma, unresectable gastric adenocarcinoma, unresectable gastroesophageal junction adenocarcinoma